Article

Once-daily drug as safe as original formula

Lrvine, CA-ISTA Pharmaceuticals Inc. said its bromfenac sodium ophthalmic solution (Xibrom) once-daily formulation produced highly statistically significant results in its phase III clinical trials.

Related Videos
Related Content
4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform
December 20th 2024

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Study validates long-term efficacy of MicroPulse TLT for glaucoma management
Published: December 19th 2024 | Updated: December 19th 2024

Study validates long-term efficacy of MicroPulse TLT for glaucoma management

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Viridian announces topline data from THRIVE-2 phase 3 clinical trial of veligrotug for treatment of thyroid eye disease
December 18th 2024

Viridian announces topline data from THRIVE-2 phase 3 clinical trial of veligrotug for treatment of thyroid eye disease

Aurion Biotech announces topline results from Phase 1/2 trial of AURN001 for corneal edema
December 18th 2024

Aurion Biotech announces topline results from Phase 1/2 trial of AURN001 for corneal edema

© 2024 MJH Life Sciences

All rights reserved.